Early trial tests Two-Pronged attack on tough tumors
Disease control
Not yet recruiting
This early-stage study is testing the safety of a new two-part treatment for advanced solid tumors. It combines a new drug, JCXH-211, injected directly into the tumor with an existing immunotherapy (anti-PD-1) given by IV. The goal is to see if this combination is safe and tolera…
Phase: PHASE1, PHASE2 • Sponsor: Immorna Biotherapeutics, Inc. • Aim: Disease control
Last updated Mar 27, 2026 12:40 UTC